Key result
Higher systolic BP is linked to ~7% lower 180-day mortality per 10 mm Hg in AHF.
Why the study?
Systolic blood pressure is an important clinical variable in acute heart failure, prompting assessment of its association with short- and long-term outcomes in a large cohort.
Is baseline systolic blood pressure associated with 180-day all-cause mortality and 14-day composite clinical outcomes in patients hospitalized with acute heart failure and preserved or reduced LVEF?
Cohort (n=10,557)
2 open-label with blinded end point evaluation (Relax-AHF-EU, Relax-AHF-Asia) and 2 double-blinded with placebo (Relax-AHF-1, RELAX-AHF-2)
1:1 ratio (except Relax-AHF-EU, which allocated 1:2 in favor of serelaxin) in parent trials
Yes
Is baseline systolic blood pressure associated with 180-day all-cause mortality and 14-day composite clinical outcomes in patients hospitalized with acute heart failure and preserved or reduced LVEF?
In patients hospitalized with acute heart failure without hypotension, lower systolic blood pressure (125–145 mm Hg) is independently associated with higher 180-day mortality in those with LVEF <40%, but shows no mortality association in those with LVEF ≥40%.
Answers are grounded in this paper and cite their sources.
Lower SBP associated with higher 180-day mortality in acute HFrEF but not HFpEF; leaves open LVEF-specific BP targets.
BACKGROUND In acute heart failure (AHF), systolic blood pressure (SBP) is an important clinical variable. This study assessed the association between SBP and short‐term and long‐term outcomes in a large cohort of patients with AHF. METHODS AND RESULTS This is an analysis of 4 randomized controlled trials investigating serelaxin versus placebo in patients admitted with AHF and SBPs from 125 to 180 mm Hg. Outcomes were 180‐day all‐cause mortality and a composite end point of all‐cause mortality, worsening heart failure, or hospital readmission for heart failure the first 14 days. Left ventricular ejection fraction (LVEF) was examined as LVEF<40% and LVEF≥40%. Multivariable Cox regression models were adjusted for known confounders of outcomes in AHF. A total of 10 533 patients with a mean age of 73 (±12) years and a mean SBP of 145 (±7) mm Hg were included. LVEF was assessed in 9863 patients (93%); 4737 patients (45%) had LVEF<40%. Increasing SBP was inversely associated with 180‐day mortality (adjusted hazard ratio [HR adjusted ], 0.93; 95% CI, 0.89–0.98; P =0.008 per 10 mm Hg increase) and with the composite end point (HR adjusted , 0.90; 95% CI, 0.85–0.94; P <0.001 per 10 mm Hg increase). A significant interaction with LVEF was observed, revealing that SBP was not associated with mortality in patients with LVEF≥40% (HR adjusted , 0.98; 95% CI, 0.91–1.04; per 10 mm Hg increase), but was strongly associated with increased mortality in LVEF<40% (HR adjusted , 0.84; 95% CI, 0.77–0.92; per 10 mm Hg increase). CONCLUSIONS Elevated SBP is associated with favorable short‐term and long‐term outcomes in patients with AHF. In our predefined subgroup analysis, we found that baseline SBP was not associated with mortality in LVEF≥40%, but was strongly associated with mortality in patients with LVEF<40%.
No takes yet. Share an insight, caveat, or question.
Grand et al. (2021) conducted a cohort in Acute heart failure (AHF) (n=10,557). Systolic blood pressure (per 10 mm Hg increase, and Group A [125-145 mm Hg] vs Group B [146-180 mm Hg]) vs. Moderately elevated SBP (Group B: 146-180 mm Hg) or continuous per 10 mm Hg lower SBP was evaluated on 180-day all-cause mortality (HR 0.93, 95% CI 0.89–0.98, p=0.008). Increasing systolic blood pressure was inversely associated with 180-day mortality in acute heart failure, driven by patients with LVEF <40%.
Synapse has enriched 10 related papers. Consider them for comparative context: